BeiGene (HKG:6160, SHA:688235) shareholder Hillhouse Capital reduced their stakes in the cancer drug manufacturer in Hong Kong, according to separate disclosures to the Hong Kong bourse on March 5.
The investment manager, through HHLR Fund and HHLR Advisors, sold 32,240,000 shares at an average price of $18.81 apiece, according to the disclosure.
Hillhouse now holds a 5.70% stake, or 79,357,423 shares, from its 111,597,423 shares, or an 8.01% stake.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.